SiSaf Ltd Announces US$13.2 Million Series B Financing

Non-invasive ocular siRNA delivery induces effective gene silencing in corneal epithelium

SiSaf announces licencing agreement to develop gene therapy for rare bone disease

SiSaf Makes Its Bio-Courier® Technology Available for COVID-19 Vaccine Research